Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation

Journal of Endocrinological Investigation

Volumn 33, Issue 10, 2010, Pages 730-738

  Comeglio, P ^a   Chavalmane, A K ^a   Fibbi, B ^a   Filippi, S ^a   Marchetta, M ^b   Marini, M ^a   Morelli, A ^a   Penna, G ^c   Vignozzi, L ^a   Vannelli, G B ^a   Adorini, L ^c   Maggi, M ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^c INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

BPH; Elocalcitol; Inflammation; RhoA ROCK; Urethra

Indexed keywords

CYCLOOXYGENASE 2; ELOCALCITOL; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 8; MESSENGER RNA; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

AGED; ARTICLE; BLADDER NECK; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RNA ISOLATION; URETHRA; URETHRITIS; WESTERN BLOTTING;

AGED; CALCITRIOL; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; HUMANS; LIGANDS; MALE; MYOCYTES, SMOOTH MUSCLE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, CALCITRIOL; URETHRA; URINARY BLADDER;

EID: 79951634976     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6974     Document Type: Article

References (57)

1. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004, 56: 581-631. (Pubitemid 40003785)
2. Patel AK, Chapple CR. Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Nat Clin Pract Urol 2008, 5: 211-9. (Pubitemid 351517129)
3. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993, 45: 253-308.
4. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002, 19: 390-6.
5. Nakai H, Yamanishi T, Yasuda K, Kitahara S, Suzuki T. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. Neurourol Urodyn 2004, 23: 618-22. (Pubitemid 39313929)
6. Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - is there a basis for pharmacological targeting of cGMP? World J Urol 2005, 23: 362-7.
7. Witjes WP, Aamink RG, Ezz-el-Din K, Wijkstra H, Debruyne EM, de la Rosette JJ. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 1997, 80: 84-90. (Pubitemid 28316715)
8. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52: 43-58. (Pubitemid 34553191)
9. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007, 51: 1202-16.
10. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007, 52: 964-72.
11. Nickel JC. Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol 1994, 1: 1-4.
12. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008, 35: 109-15. (Pubitemid 350166524)
13. Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004, 150: 591-603. (Pubitemid 38584712)
14. Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005, 90: 962-72. (Pubitemid 40279222)
15. Morelli A, Vignozzi L, Filippi S, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 2007, 67: 234-47.
16. Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J Endocrinol Invest 2006, 29: 665-74. (Pubitemid 44446280)
17. Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007, 103: 689-93. (Pubitemid 46401347)
18. Penna G, Fibbi B, Amuchastegui S, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009, 69: 480-93.
19. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4: 404-12.
20. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003, 138: 757-66. (Pubitemid 36390631)
21. Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther 2004, 308: 54-8. (Pubitemid 38090699)
22. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004, 309: 1148-53. (Pubitemid 38669703)
23. Takahashi R, Nishimura J, Hirano K, Seki N, Naito S, Kanaide H. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004, 172: 748-52. (Pubitemid 38900254)
24. Segain JP, Raingeard de la Blétière D, Sauzeau V, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003, 124: 1180-7. (Pubitemid 36531793)
25. He Y, Xu H, Liang L, et al. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 2008, 58: 3366-76.
26. Masamune A, Kikuta K, Satoh M, Satoh K, Shimosegawa T. Rho kinase inhibitors block activation of pancreatic stellate cells. Br J Pharmacol 2003, 140: 1292-302. (Pubitemid 38117434)
27. Low JA, Armstrong JB, Mauger GM. The unstable urethra in the female. Obstet Gynecol 1989, 74: 69-74.
28. Roehrborn CG, McConnell JD, Saltzman B, et al; PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002, 42: 1-6.
29. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001, 166: 172-6. (Pubitemid 32565372)
30. Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 2003, 91: 196-200. (Pubitemid 36232834)
31. Crescioli C, Maggie M, Vannelli GB, et al. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000, 85: 2576-83. (Pubitemid 32269218)
32. Morelli A, Chavalmane AK, Filippi S, et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009, 6: 91-106.
33. Matsumura F, Hartshorne DJ. Myosin phosphatase target subunit: Many roles in cell function. Biochem Biophys Res Commun 2008, 369: 149-56.
34. Kawanabe Y, Okamoto Y, Nozaki K, Hashimoto N, Miwa S, Masaki T. Molecular mechanism for endothelin-1-induced stress-fiber formation: analysis of G proteins using a mutant endothelin(A) receptor. Mol Pharmacol 2002, 61: 277-84 (Pubitemid 34112801)
35. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008, 199: 237-47.
36. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003, 164: 29-42.
37. Gombart AF, O'Kelly J, Saito T, Koeffler HP. Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 2007, 103: 552-7.
38. Mong A, Bellah R. Imaging the pediatric prostate. Radiol Clin North Am 2006, 44: 749-56. (Pubitemid 44498740)
39. Levin TL, Han B, Little BP. Congenital anomalies of the male urethra. Pediatr Radiol 2007, 37: 851-62. (Pubitemid 47190353)
40. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007, 26 (6 Suppl): 948-54. (Pubitemid 47548232)
41. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83: 1325-58. (Pubitemid 37222274)
42. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001, 22: 32-9. (Pubitemid 32126284)
43. Worthylake RA, Burridge K. RhoA and ROCK promote migration by limiting membrane protrusions. J Biol Chem 2003, 278: 13578-84. (Pubitemid 36800134)
44. Largiadèr T, Eto M, Payeli SK, et al. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol 2008, 52: 369-74.
45. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69: 145-82.
46. Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, Garofalo RP. A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells. Dependence on nuclear abundance of ReI A, NF-kappaB1, and c-Rel transcription factors. J Biol Chem 1998, 273: 3551-61. (Pubitemid 28109779)
47. Montaner S, Perona R, Saniger L, Lacal JC. Activation of serum response factor by RhoA is mediated by the nuclear factor-kappaB and C/EBP transcription factors. J Biol Chem 1999, 274: 8506-15. (Pubitemid 29164640)
48. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003, 83: 1131-46. (Pubitemid 37013048)
49. Fichera A, Little N, Dougherty U, et al. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res 2007, 142: 239-45. (Pubitemid 47418822)
50. Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006, 26: 2525-30. (Pubitemid 44155531)
51. Shimizu S, Tahara M, Ogata S, et al. Involvement of nuclear factor-kB activation through RhoA/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells. Mol Hum Reprod 2007, 13: 181-7.
52. Sun J, Kong J, Duan Y, et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006, 291: E315-22.
53. Dong X, Craig T, Xing N, et al. Direct transcriptional regulation of RelB by 1 alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem 2003, 278: 49378-85.
54. Penna G, Amuchastegui S, Giarratana N, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007, 178: 145-53. (Pubitemid 46033595)
55. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004, 173: 2280-7. (Pubitemid 39063083)
56. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27: 1883-93. (Pubitemid 44288669)
57. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1alpha,25- dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 1997, 250: 63-71. (Pubitemid 27504583)